Loading…
Pan-India diagnostics chain offering pathology testing through labs, collection centres and hospital partnerships.
Pan-India diagnostics chain offering pathology testing through labs, collection centres and hospital partnerships.
Gets paid per test, from patients who walk in or are visited at home, from doctors and hospitals that send samples, and from corporate health-check contracts, with higher-priced specialised tests lifting the mix. It has widened its network partly by buying regional lab chains.
In one line: India's LabCorp-style diagnostics network.
Moat: narrow (brand, scale, distribution). Large pan-India lab network and brand trust, competing closely with Dr. Lal PathLabs for share.
Headquarters: Mumbai, India · Founded: 1980 · Employees: 4,844
Size Metropolis Healthcare (METROPOLIS.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $1.25B, the 534th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹568.75 on 6 Nov 2026.
Performance Over six months the shares gained 12.5%, against +21.3% for the median peer and 0.0% for the India market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 19.8% over the last twelve months (peer median +7.3%); the operating margin is 17.6% (peer median 5.0%).
Valuation It trades at 45.6× forward earnings against a peer median of 25.1× (4th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.9 points above its cost of capital (12.8% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹17.8B | ₹16.5B | ₹13.3B | ₹12.1B | ₹11.5B |
| Revenue growth | — | +24% | +10% | +5% | — |
| Gross profit | ₹8.73B | ₹7.34B | ₹5.75B | ₹5.36B | ₹5.10B |
| EBITDA | ₹4.48B | ₹4.09B | ₹3.14B | ₹3.00B | ₹3.03B |
| Net income | ₹2.24B | ₹1.90B | ₹1.45B | ₹1.28B | ₹1.43B |
| Free cash flow | n/a | ₹2.99B | ₹2.21B | ₹1.99B | ₹1.90B |
| Capital expenditure | n/a | ₹512M | ₹686M | ₹638M | ₹526M |
| Total debt | ₹2.68B | ₹2.32B | ₹2.04B | ₹1.97B | ₹2.66B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Metropolis Healthcare METROPOLIS.NS | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% |
| Dr. Lal PathLabs LALPATHLAB.NS | $3.50B | +26% | +17% | 24% | 51.5× | 32.2% |
| Vijaya Diagnostic Centre VIJAYA.NS | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% |
| Thyrocare Technologies THYROCARE.NS | $830M | +5% | +22% | 26% | 35.2× | 27.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | METROPOLIS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.0% | +5.7% | 11th highest of 21 |
| 6-month return | +12.5% | +21.3% | 8th lowest of 21 |
| Distance from 52-week high | -6.6% | -17.1% | 4th highest of 21 |
| Revenue growth (TTM) | +19.8% | +7.3% | 5th highest of 21 |
| Operating margin | 17.6% | 5.0% | 3rd highest of 21 |
| Forward P/E | 45.6× | 25.1× | 4th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 32.4% | 14.8% | 4th most demanding of 17 |
| Growth delivered (Del g) | +10.5% | +13.7% | 8th lowest of 17 |
| Hurdle (Req g minus delivered) | +21.9 pp | +1.0 pp | 3rd most demanding of 17 |
| ROIC minus cost of capital | +1.9 pp | -3.7 pp | 5th highest of 20 |
| EV / EBITDA | 26.2× | 11.6× | 6th most expensive of 17 |
| Net debt / EBITDA | -0.2× | 1.3× | 4th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |